We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the last reported quarter, the company beat earnings expectations by 17.8%. The ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

The FDA has approved tarlatamab (Imdelltra; Amgen), a novel bispecific T-cell engager, to treat patients with extensive-stage small cell lung cancer (SCLC).